Development and validation of a novel risk assessment model for necrotizing fasciitis in patients with diabetic foot
Exploration of Endocrine and Metabolic Diseases · 12.03.2026 · 3
DOI: 10.37349/eemd.2026.101463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Endocrine and Metabolic Diseases, online erschienen am 12.03.2026. Verfasst von Xun Li und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Aim
Necrotizing fasciitis (NF) is a severe and early challenging-to-identify complication of diabetic foot (DF). This study aimed to develop and validate a novel risk assessment model for NF with DF patients utilizing conventional clinical indicators.
Methods
A retrospective analysis was conducted on 815 DF patients admitted to the First Affiliated Hospital of Chongqing Medical University between October 2018 and April 2022. Based on the presence of NF, patients were stratified into a DF group (n = 703) and a DF complicated with NF (DNF) group (n = 112). Clinically and statistically significant variables were converted into categorical form. A new risk assessment for DNF (NRADNF) nomogram was developed via multivariable stepwise logistic regression. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) for discriminative ability, the Hosmer-Lemeshow goodness-of-fit test for calibration, decision curve analysis (DCA) for clinical utility, and bootstrap resampling for stability.
Results
The final NRADNF model incorporated six indicators: age < 60 years, body temperature ≥ 38°C, foot skin necrosis, neutrophil-to-lymphocyte ratio (NLR) ≥ 8.5, hypersensitive C-reactive protein > 20 mg/L, and hemoglobin ≤ 100 g/L. The model demonstrated favorable predictive performance with an AUC of 0.815 (95% CI: 0.773, 0.857), and it was significantly superior to the RADNF model by our team (P = 0.027). Calibration curves and the Hosmer-Lemeshow test indicated good accuracy. DCA confirmed the model’s clinical net benefit, and internal validation via bootstrap resampling supported its stability.
Conclusions
Based on its favorable predictive performance and accessible indicators, the NRADNF model is suitable for preliminary screening of DNF in clinical practice.
Zitieren
APA
Li, X., Zhang, X., Cheng, C., Ni, X., Huang, Q., Tang, Z., Zhao, W., Du, Z., Zeng, Q., & Cheng, Q. (2026). Development and validation of a novel risk assessment model for necrotizing fasciitis in patients with diabetic foot. Exploration of Endocrine and Metabolic Diseases, 3. https://doi.org/10.37349/eemd.2026.101463
Vancouver
Li X, Zhang X, Cheng C, Ni X, Huang Q, Tang Z, et al. Development and validation of a novel risk assessment model for necrotizing fasciitis in patients with diabetic foot. Exploration of Endocrine and Metabolic Diseases. 2026;3. doi:10.37349/eemd.2026.101463
BibTeX
@article{Li2026,
author = {Li, Xun and Zhang, Xiaoru and Cheng, Chao and Ni, Xia and Huang, Qiuhong and Tang, Ziwei and Zhao, Wenrui and Du, Zhipeng and Zeng, Qinglian and Cheng, Qingfeng},
title = {Development and validation of a novel risk assessment model for necrotizing fasciitis in patients with diabetic foot},
journal = {Exploration of Endocrine and Metabolic Diseases},
year = {2026},
volume = {3},
doi = {10.37349/eemd.2026.101463}
}
EUVIMED